EA201891727A1 - Композиции на основе дейтерированного домперидона и способы терапии расстройств - Google Patents

Композиции на основе дейтерированного домперидона и способы терапии расстройств

Info

Publication number
EA201891727A1
EA201891727A1 EA201891727A EA201891727A EA201891727A1 EA 201891727 A1 EA201891727 A1 EA 201891727A1 EA 201891727 A EA201891727 A EA 201891727A EA 201891727 A EA201891727 A EA 201891727A EA 201891727 A1 EA201891727 A1 EA 201891727A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
deuterated
methods
domperidon
disorders
Prior art date
Application number
EA201891727A
Other languages
English (en)
Other versions
EA035515B1 (ru
Inventor
Кэтрин Пирс
Джон Айзаксон
Пиюш Патель
Original Assignee
СИНРКС ФАРМА, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СИНРКС ФАРМА, ЭлЭлСи filed Critical СИНРКС ФАРМА, ЭлЭлСи
Publication of EA201891727A1 publication Critical patent/EA201891727A1/ru
Publication of EA035515B1 publication Critical patent/EA035515B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к композициям домперидона, способам и дозирующим составам, обеспечивающим предпочтительные характеристики безопасности и другие полезные эффекты дейтерированного домперидона, а также к получению дейтерированных аналогов домперидона.
EA201891727A 2016-02-04 2017-02-03 Композиции на основе дейтерированного домперидона и способы терапии расстройств EA035515B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291198P 2016-02-04 2016-02-04
PCT/US2017/016334 WO2017136617A1 (en) 2016-02-04 2017-02-03 Deuterated domperidone compositions and methods for therapy of disorders

Publications (2)

Publication Number Publication Date
EA201891727A1 true EA201891727A1 (ru) 2018-12-28
EA035515B1 EA035515B1 (ru) 2020-06-29

Family

ID=59501077

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201891727A EA035515B1 (ru) 2016-02-04 2017-02-03 Композиции на основе дейтерированного домперидона и способы терапии расстройств
EA202090183A EA202090183A1 (ru) 2016-02-04 2018-06-28 Композиции, способы и получение дейтерированного домперидона

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202090183A EA202090183A1 (ru) 2016-02-04 2018-06-28 Композиции, способы и получение дейтерированного домперидона

Country Status (10)

Country Link
US (2) US10266516B2 (ru)
EP (2) EP3411031A4 (ru)
JP (3) JP7296185B2 (ru)
KR (2) KR20180104662A (ru)
CN (4) CN113995755A (ru)
AU (2) AU2017213852B2 (ru)
BR (2) BR112018016032B1 (ru)
CA (2) CA3013123A1 (ru)
EA (2) EA035515B1 (ru)
WO (2) WO2017136617A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017136617A1 (en) * 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
AU2019290231A1 (en) * 2018-06-21 2020-12-17 Dermavant Sciences GmbH Topical formulations of DGAT1 inhibitors and their methods of use
KR20210082480A (ko) * 2018-10-25 2021-07-05 신돔 파마, 인크. 돔페리돈을 함유하는 제제
AU2019366993B2 (en) * 2018-10-25 2024-02-15 Cindome Pharma, Inc. Formulations containing deuterated domperidone
US20220307004A1 (en) * 2021-03-29 2022-09-29 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Multi-Enzyme Nanoparticle-Assisted Stable Isotope Incorporation Into Small Molecules by Channeling
WO2023205368A1 (en) * 2022-04-20 2023-10-26 Cindome Pharma, Inc. Deuterated domperidone for treating gastroparesis

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
TW466119B (en) * 1994-02-28 2001-12-01 Janssen Pharmaceutica Nv Film coated tablet of paracetamol and domperidone
FR2725986B1 (fr) * 1994-10-21 1996-11-29 Adir Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US20140163060A1 (en) 2001-10-12 2014-06-12 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20130220526A1 (en) 2001-10-12 2013-08-29 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20140070440A1 (en) 2001-10-12 2014-03-13 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20160206639A9 (en) 2001-10-12 2016-07-21 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
ITMI20020514A1 (it) 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
HUE031650T2 (en) 2002-10-01 2017-07-28 Banner Life Sciences Llc Enterosolvent preparation for soft capsule wall production
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
JP6091041B2 (ja) 2004-12-31 2017-03-08 イシューティカ ピーティーワイ リミテッド ナノ粒子組成物及びその合成方法
ITMI20050477A1 (it) 2005-03-23 2006-09-24 Bouty S P A Cerotto transdermico
CN100386323C (zh) * 2006-02-27 2008-05-07 南京长澳医药科技有限公司 马来酸多潘立酮的合成方法
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
NZ599069A (en) 2006-06-30 2013-10-25 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form
WO2008134540A1 (en) 2007-04-26 2008-11-06 Aronchick Craig A Compositions and methods for transmucosal delivery of domperidone
JP5345620B2 (ja) 2007-08-15 2013-11-20 マクニール−ピーピーシー・インコーポレーテツド 即時放出及び徐放型イブプロフェンの投与法
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090076010A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
WO2009146310A1 (en) 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
US20100113405A1 (en) * 2008-11-06 2010-05-06 Auspex Pharmaceuticals, Inc. Methylindazole modulators of 5-ht3 receptors
US20100120733A1 (en) 2008-11-07 2010-05-13 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
CN104000785B (zh) 2009-04-24 2021-01-05 伊休蒂卡有限公司 美他沙酮的新剂型
DK2421513T3 (en) 2009-04-24 2018-03-26 Iceutica Pty Ltd UNKNOWN FORMULATION WITH INDOMETHACIN
MX344838B (es) 2009-04-24 2017-01-09 Iceutica Pty Ltd Metodo para la produccion de polvos de nanoparticulas y microparticulas comerciales.
MX344222B (es) 2009-04-24 2016-12-07 Iceutica Pty Ltd Una formulacion novedosa de naproxeno.
EP3290030A1 (en) 2009-04-24 2018-03-07 Iceutica Pty Ltd. Diclofenac formulation
US20140017299A1 (en) 2011-08-18 2014-01-16 Monosol Rx, Llc Steroid hormone delivery systems and methods of preparing the same
US8871245B2 (en) 2012-02-28 2014-10-28 Nichiban Co., Ltd. Transdermal patch
US20150197525A1 (en) 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
CN104781272A (zh) 2012-06-19 2015-07-15 英特塞普特医药品公司 奥贝胆酸的制备、用途和固体形式
US20140019395A1 (en) 2012-07-12 2014-01-16 Craig Charles Bauer Method and application of Fear, Love and Methodology as protocols within and of a programming group, as a means of creating an artificial individual, software system or other independent entity capable of independent self directive creation of choice and/or self directive creation of purpose within a virtual and/or any environment
EP2968334A4 (en) 2013-03-14 2016-08-03 Deuterx Llc 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
US20140271787A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Continuous single layer film structure including discrete domains
US20140272220A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Reduction in stress cracking of films
EP2969227B1 (en) 2013-03-15 2019-05-08 Iceutica Inc. Abiraterone acetate formulation
WO2017136617A1 (en) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation

Also Published As

Publication number Publication date
JP2020534246A (ja) 2020-11-26
US10590110B2 (en) 2020-03-17
BR112018016032B1 (pt) 2024-03-05
KR20200044790A (ko) 2020-04-29
JP2023052045A (ja) 2023-04-11
AU2018290905A1 (en) 2020-02-13
AU2018290905B2 (en) 2022-10-06
CN111093653A (zh) 2020-05-01
US20190241543A1 (en) 2019-08-08
EA035515B1 (ru) 2020-06-29
BR112019028185A8 (pt) 2020-08-11
AU2017213852B2 (en) 2021-04-08
WO2017136617A1 (en) 2017-08-10
CN113995755A (zh) 2022-02-01
AU2017213852A1 (en) 2018-07-05
BR112018016032A2 (pt) 2018-12-26
EA202090183A1 (ru) 2020-04-15
EP3644995A1 (en) 2020-05-06
WO2019006078A1 (en) 2019-01-03
CN116712432A (zh) 2023-09-08
CA3055777A1 (en) 2019-01-03
JP2019504068A (ja) 2019-02-14
JP7296185B2 (ja) 2023-06-22
CN108697700A (zh) 2018-10-23
EP3411031A1 (en) 2018-12-12
US10266516B2 (en) 2019-04-23
CN108697700B (zh) 2021-08-17
KR20180104662A (ko) 2018-09-21
CN111093653B (zh) 2023-06-23
WO2017136617A8 (en) 2017-10-05
EP3411031A4 (en) 2019-08-07
BR112019028185A2 (pt) 2020-07-07
CA3013123A1 (en) 2017-08-10
US20170298046A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
EA201891727A1 (ru) Композиции на основе дейтерированного домперидона и способы терапии расстройств
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201790806A1 (ru) Иммунорегулирующие средства
EA201991183A1 (ru) Новые ингибиторы глутаминазы
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201890908A1 (ru) Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений
EA201790434A1 (ru) Модуляторы каналов
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201691582A1 (ru) Новые фармацевтические препараты
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EA201492002A1 (ru) Противовирусные соединения
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA201791174A1 (ru) Антимикотическое соединение
EA201790570A1 (ru) Модуляторы р2х7
EA201791009A1 (ru) Композиции, содержащие циклоспорин
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM